Insulin demand regulates β cell number via the unfolded protein response

Rohit B. Sharma,1 Amy C. O’Donnell,2 Rachel E. Stamateris,1 Binh Ha,1 Karen M. McCloskey,2 Paul R. Reynolds,3 Peter Arvan,4 and Laura C. Alonso1

1Diabetes Division, Department of Medicine, University of Massachusetts (UMass) Medical School, Worcester, Massachusetts, USA. 2University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 3Department of Pediatrics, National Jewish Health, Denver, Colorado, USA. 4Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan, USA.

Although stem cell populations mediate regeneration of rapid turnover tissues, such as skin, blood, and gut, a stem cell reservoir has not been identified for some slower turnover tissues, such as the pancreatic islet. Despite lacking identifiable stem cells, murine pancreatic β cell number expands in response to an increase in insulin demand. Lineage tracing shows that new β cells are generated from proliferation of mature, differentiated β cells; however, the mechanism by which these mature cells sense systemic insulin demand and initiate a proliferative response remains unknown. Here, we identified the β cell unfolded protein response (UPR), which senses insulin production, as a regulator of β cell proliferation. Using genetic and physiologic models, we determined that among the population of β cells, those with an active UPR are more likely to proliferate. Moreover, subthreshold endoplasmic reticulum stress (ER stress) drove insulin demand–induced β cell proliferation, through activation of ATF6. We also confirmed that the UPR regulates proliferation of human β cells, suggesting that therapeutic UPR modulation has potential to expand β cell mass in people at risk for diabetes. Together, this work defines a stem cell–independent model of tissue homeostasis, in which differentiated secretory cells use the UPR sensor to adapt organ size to meet demand.

Introduction

Diabetes occurs when pancreatic β cells fail to meet insulin demand, due to loss of β cell mass and function (1, 2). In the end-stage spiral that leads to diabetes, β cell mass and function are linked via decompensated endoplasmic reticulum stress (ER stress). Severely overworked β cells are more likely to die, leading to loss of β cell mass; β cell loss increases stress on remaining β cells, impairing their function (3–7). For both type 1 and type 2 diabetes, an important therapeutic goal is to find tools to regenerate β cells, so as to restore endogenous insulin production capacity. Some strains of mice robustly increase β cell number in response to increased insulin demand (8). No local stem cell population has been found in islets, nor do hematogenous stem cells participate in β cell expansion (9). Lineage-tracing studies show that the primary means of generating new β cells in adult mice is proliferation of fully differentiated, mature β cells (10, 11). In fact, all β cells are reported to have equal potency to generate new β cells, implying a different model of tissue homeostasis in which the proliferative reservoir consists of fully differentiated cells (12, 13). Since the rate of β cell proliferation is strongly influenced by the metabolic environment of the host (14–16), in some cases tramping islet-intrinsic factors (17, 18), the working model in the field has been that circulating factors regulate β cell proliferation. Many different signals have been proposed to drive β cell proliferation in response to insulin demand, principally nutrients (14, 15, 19, 20) and growth factors (8, 21–23). However, no circulating signal explains all the observations, and models in which a distant organ senses insulin demand and directs β cells to proliferate are complicated and indirect.

Here, we present evidence supporting a simpler hypothesis: that the β cell itself senses unmet insulin demand via activation of unfolded protein response (UPR) secretory peptide synthesis sensors, which trigger a proliferative response. When demand increases, it is well established that β cells increase proinsulin synthesis, activating the UPR (3, 7). We find that β cells with active UPR are more likely to proliferate, that engaging mild additional ER stress increases proliferation in the context of high glucose, and that UPR activation is required for driving proliferation in several different models. We trace the proliferative signal to the ATF6 pathway and verify that UPR also regulates proliferation in human β cells (all instances of Atf6 refer to Atf6α). Taken together, these findings outline a mechanism by which insulin demand regulates β cell number and suggest a model of tissue homeostasis, independent of stem cells, in which secretory cells use the UPR mechanism to sense demand and increase cell number when demand exceeds capacity.

Results

Proteomics screen to identify in vivo drivers of β cell proliferation reveals activation of the UPR without decompensation. Hyperglycemia increases insulin demand. In mice, modestly raising blood glucose by direct i.v. glucose infusion increases β cell proliferation (15, 24, 25). To identify new pathways driving β cell proliferation, islets were isolated after a 4-day exposure to either normal or elevated blood glucose (Supplemental Figure 1; supplemental material...
Hyperglycemia in vivo (Figure 1, G–J). Thus, moderate continuous hyperglycemia in vivo, a condition that stimulates β cell proliferation, also leads to UPR activation without decompensation.

To facilitate testing the relationship between UPR and proliferation, an ex vivo model was developed in which freshly isolated primary dispersed mouse islet cells were cultured in low or high glucose. Ex vivo glucose exposure recapitulated the in vivo induction of peptide folding, ER-associated degradation, and secretory pathway members detected in the proteomics screen (Supplemental Figure 2A). Glucose treatment increased proliferation, as measured by BrdU (Figure 2, A and B), Ki67, and Pcna (Figure 2, C and D). Glucose also induced the UPR, as indicated by increased abundance of BiP and calreticulin (Figure 2E), spliced Xbp (Figure 2F), p-eIF2α, ATF6 (Figure 2, G and H), and known transcriptional targets of ATF6 and XBP (Figure 2, I and J), while reducing decompensation marker CHOP (Figure 2K). Quantifications of these immunoblots, and additional data, are found in Supplemental Figure 2, B–K, and Supplemental Figure 3. Thus, pancreatic islets responding to increased insulin demand created hyperglycemia in vivo (Figure 1, G–J). Thus, moderate continuous hyperglycemia in vivo, a condition that stimulates β cell proliferation, also leads to UPR activation without decompensation.

To facilitate testing the relationship between UPR and proliferation, an ex vivo model was developed in which freshly isolated primary dispersed mouse islet cells were cultured in low or high glucose. Ex vivo glucose exposure recapitulated the in vivo induction of peptide folding, ER-associated degradation, and secretory pathway members detected in the proteomics screen (Supplemental Figure 2A). Glucose treatment increased proliferation, as measured by BrdU (Figure 2, A and B), Ki67, and Pena (Figure 2, C and D). Glucose also induced the UPR, as indicated by increased abundance of BiP and calreticulin (Figure 2E), spliced Xbp (Figure 2F), p-eIF2α, ATF6 (Figure 2, G and H), and known transcriptional targets of ATF6 and XBP (Figure 2, I and J), while reducing decompensation marker CHOP (Figure 2K). Quantifications of these immunoblots, and additional data, are found in Supplemental Figure 2, B–K, and Supplemental Figure 3. Thus, pancreatic islets responding to increased insulin demand created hyperglycemia in vivo (Figure 1, G–J). Thus, moderate continuous hyperglycemia in vivo, a condition that stimulates β cell proliferation, also leads to UPR activation without decompensation.
by hyperglycemia in vivo or in vitro activate both proliferation and UPR without decompensation.

**β cells with active UPR are more likely to proliferate.** Islets contain a mixed population of cells, including considerable heterogeneity among β cells themselves. Within the β cell population, we hypothesized that some cells might activate UPR due to increased insulin production, while a different subpopulation might respond by proliferating. To assess UPR activation on a per-cell basis, pancreas sections were immunostained for BiP. BiP expression was heterogeneous among insulin-positive cells, and exposure to hyperglycemia in vivo increased the proportion of β cells with high BiP expression (Figure 3, A and B). In vitro glucose treatment also increased the number of β cells containing high levels of BiP (Figure 3C). To determine whether β cells with active UPR were the same or different β cells than those that proliferate, pancreas sections were communostained for insulin, BiP, and PCNA. Surprisingly, visual observation suggested that many β cells positive for PCNA also had high BiP expression (Figure 3, D–G). Quantification confirmed that β cell proliferation was actually more frequent in cells with evidence of active UPR in mice exposed to hyperglycemia (Figure 3H). This relationship was absent in unstressed normoglycemic mice (saline infusion, Figure 3I). To learn whether this observation was unique to the hyperglycemic environment or might be a feature of increased insulin demand, we repeated the experiment in a second model of β cell adaptation, the high-fat diet–fed mouse (HFD-fed mouse) (28). β cell proliferation was more frequent in cells with active UPR in these mice, as well (Figure 3I), despite having normal blood glucose (control diet 144 ± 8 mg/dl, high-fat diet 127 ± 11 mg/dl), suggesting that increased proliferation in β cells with active UPR may be a general feature of insulin-demand compensation.

We confirmed the correlation between active UPR and proliferation in primary dispersed mouse β cells in vitro. Culturing mouse islet cells in 15 mM glucose increased both β cell proliferation and total cell number (Figure 3, J and K). In these cultures also, cells with high BiP levels were more likely to incorporate BrdU (Figure 3, L–N). To test whether UPR activation might be a consequence of preparing to enter the cell cycle, we assessed BiP levels in β cells induced to proliferate by direct manipulation of the cell cycle. In β cells overexpressing cyclin D2, many BrdU-incorporating cells had medium or low levels of BiP, arguing...
Gentle UPR activation increases β cell proliferation in vitro in the context of high glucose. Despite the abundant evidence in the literature that decompensated ER stress causes β cell death (3–7), the observed correlation between UPR and proliferation led us to against the explanation that a correlation between BiP and proliferation is due to induction of BiP during proliferation (Figure 3O). Taken together, we conclude that β cells with active UPR are more likely to proliferate than β cells without active UPR.
Figure 4. Activating mild UPR ex vivo increases β cell proliferation and β cell number. (A and B) In primary mouse islet cells, PCNA induced by 15 mM glucose was further increased by low-dose Tg (2–20 nM) or Tm (10–100 ng/ml). A marked drug-dose threshold was apparent; at higher doses of Tg or Tm, PCNA was abruptly lost and decompensation markers CHOP (A) and activated caspase 3 (B) were induced. Numbers below bands are average band intensity quantification of n = 5–7 immunoblots; plots of averages are found in Supplemental Figure 4. *P < 0.05 vs. 15 mM vehicle. (C–E) Mouse islet cells treated with low-dose Tg or Tm increased proliferation in high glucose (n = 3). (F and G) Proliferation was confirmed by phospho-Histone H3 (n = 3). (H) Expression of Akita proinsulin increased β cell proliferation (n = 5). (I–L) Quantitative cell counting using flow cytometry showed increased β cell number in cultures treated with low-dose Tg and Tm (n = 5–7). (J and K) Low-dose Tg did not induce cell death (n = 4). (C and F) Images acquired at ×200 magnification. Data are represented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001, and †P < 0.0001 by ANOVA. P values in A, B, G, and I–L are vs. 15 mM vehicle.
consider the hypothesis that modest UPR activation might actually promote β cell proliferation. To test this, primary mouse islet cells were cultured with small molecules that induce ER stress by different mechanisms, by interfering with ER calcium handling (thapsigargin, Tg) or glycosylation (tunicamycin, Tm). Since the usual concentrations of these agents (1 μM for Tg and 1–10 μg/ml for Tm) induce decompensated ER stress and cell death, we applied a broad range of concentrations, starting with 2–3 orders of magnitude lower than the usual dose. Assessing decompensated ER stress by immunoblot for CHOP or caspase 3, we confirmed that these drugs in usual concentrations induce severe ER stress and cell death in primary mouse islet cells (Figure 4, A and B, and Supplemental Figure 4). By PCNA immunoblot, high glucose induced proliferation, as expected. Intriguingly, low doses of either Tg or Tm further increased PCNA abundance in islet cells cultured in 15 mM glucose, with an abrupt dose threshold above which PCNA disappeared and CHOP and caspase 3 were induced. To determine whether increased PCNA abundance in the mixed islet cell population represented increased β cell proliferation, cultures were treated with low-dose Tg or Tm and assayed for proliferation by BrdU incorporation. Remarkably, in 15 mM glucose, both drugs increased mouse β cell proliferation over vehicle control (Figure 5, D–H). ER stress applied directly to the β cell is sufficient to increase β cell proliferation in vivo. (F–H) Heterozygous Akita mice had normal blood glucose and body weight at 2 and 3 weeks of age but developed hyperglycemia at 4 weeks (n = 4–22). Pancreas sections showed UPR activation was already present at 2 weeks of age (I–K). BrdU incorporation was elevated at 2 and 3 weeks of age, when UPR was active but before decompensation began (n = 3–5). (K) Proliferation in Akita β cells at 2–3 weeks of age was confirmed using PCNA staining (n = 5–11). (D, E, H, and I) Images acquired at ×200 magnification. Data are represented as mean ± SEM; *P < 0.05, **P < 0.01, and ***P < 0.001 by Student’s t test.
5 mM glucose (usual islet culture medium), low-dose Tg and Tm induced visible toxicity with cell loss and absence of proliferation, while a proliferative effect was seen in 10–15 mM glucose. Given concerns in the field that BrdU incorporation does not always indicate cell proliferation, we further confirmed the PCNA immunoblot and BrdU immunostaining with phospho-histone H3 (pHH3) immunostaining, a marker of mitosis. Both Tg and Tm increased the percent of β cells staining for pHH3 (Figure 4, F and G). To test whether directly stressing the ER could increase β cell proliferation, mouse islet cells were transduced with adenovirus expressing Ins2\(^{2\text{99G}}\) (Akita). Akita proinsulin expression also increased β cell BrdU incorporation (Figure 4H). In addition to histochemical assessment of proliferation, we hypothesized that increased proliferation should increase the number of cells in the culture wells. By flow cytometry, culture in 15 mM glucose increased the number of islet cells and β cells, but not α cells, over 5 mM controls (Figure 4, I–K, and Supplemental Figures 6 and 7). Low-dose Tg and low-dose Tm, but not high-dose Tg, increased the number of β cells in the culture wells, again supporting a proliferative effect. Comparative cell counts include both addition of proliferating cells in some samples and loss of dying cells in others, such as in the 5 mM glucose condition (see below). Although we did not expect low-dose Tg and Tm exposure to cause cell death, because CHOP and activated caspase 3 were low (Figure 4, A and B), we directly measured cell death by Annexin V/propidium iodide staining (Figure 4L and Supplemental Figure 8). As expected, cell death was strongly detected in the positive control (high-dose Tg) but was low in primary islet cells exposed to proliferative-dose Tg, comparable to 15 mM glucose control. Cell death was increased in the 5 mM glucose condition, possibly explaining the apparent heightened sensitivity to Tg and Tm in low glucose, and contributing to the difference in cell number between 5 mM and 15 mM glucose on flow counts. Finally, to exclude the possibility that BrdU incorporation was an artifact of DNA damage, cultures were coimmunostained for PCNA and p-IRE1, and ATF6 (Figure 6A). Immunoblot for PCNA suggested increases in islet cells overexpressing cyclin D2, suggesting the result was consistent with our hypothesis, β cell proliferation, as measured by BrdU staining, developing at 3–4 weeks (Figure 5, H and I). Again consistent with our hypothesis, β cell proliferation, as measured by BrdU incorporation and confirmed by PCNA staining, was increased at 2 weeks, less so at 3 weeks, and was no longer elevated at 4 weeks, when severe stress was evident (Figure 5, I–K). Thus, β cell proliferation was elevated in both db/db and Akita mice early after the onset of ER stress but was lost when islets were depleted. In sum, 4 distinct ER stressors — interference with ER calcium handling, blockage of ER protein glycosylation, leptin-receptor deficiency in a β cell ER stress–sensitive background, and loading of misfolded proinsulin in the ER — all resulted in increased β cell proliferation. These data are consistent with the hypothesis that mild or early UPR promotes β cell proliferation.

**UPR activation is required for insulin-demand-induced β cell proliferation in vitro and in vivo.** To learn whether UPR activation is required for the β cell proliferative response to glucose ex vivo, we applied 2 chemical chaperones — tauroursodeoxycholic acid (TUDCA) and 4-phenylbutyrate (PBA), which reduce ER stress — to islet cell cultures. Both chemical chaperones reduced glucose-induced ER stress in islet cultures, with reductions in p-eIF2α, p-IRE1, and ATF6 (Figure 6A). Immunoblot for PCNA suggested that both chaperones also reduced glucose-induced islet cell proliferation (Figure 6, B and C). Using immunofluorescence to evaluate chaperone effects specifically on β cell proliferation, we confirmed that addition of either chaperone prevented the increase in β cell proliferation induced by glucose (Figure 6, D and E). To exclude the possibility that the drugs nonspecifically inhibit some mechanism required for cell division or incorporation of the BrdU label, we repeated the experiment while activating the cell cycle by overexpressing cyclin D2. The chaperones again blocked proliferation induced by glucose but had no effect on BrdU incorporation in islet cells overexpressing cyclin D2, suggesting the result was not due to nonspecific toxicity (Figure 6, F and G).

To test whether ER stress is required for insulin-demand-induced β cell proliferation in vivo, mouse models with increased β cell ER load were treated with control or i.p. TUDCA injections for 2 days prior to euthanasia. Immunofluorescence of pancreas sections showed that TUDCA exposure reduced the abundance of ER stress marker BiP in β cells (Figure 7A). TUDCA treatment significantly reduced β cell proliferation in Akita (Figure 7, B and C), but not in DBA/2 mice (Figure 7, D and E), and HFD-fed mice (Figure 7, F and G), without lowering blood glucose over this time frame (Supplemental Figure 10) or preventing intestinal BrdU incor-
In contrast, none of these inhibitors reduced cell-cycle entry caused by cyclin D2 overexpression, arguing against non-specific toxicity (Figure 8A). Immunoblots showed that the ATF6 and IRE1 inhibitors, but not the PERK inhibitor, also reduced PCNA abundance in primary islet cell cultures (Figure 8B). To test whether activating the IRE1 or ATF6 pathways induced β cell proliferation, electroporation was used to overexpress IRE1, spliced (active) XBP1, or ATF6 in primary mouse islet cells (Figure 8, C–G, and Supplemental Figure 12). Surprisingly, given that the IRE1 inhibitor reduced proliferation, overexpression of either IRE1 or sXBP1 also reduced β cell proliferation in 15 mM glucose (Figure 8, D and G). ATF6 overexpression, however, was sufficient to increase β cell proliferation (Figure 8G). To test whether IRE1 or ATF6 were required for glucose-induced proliferation, expression was reduced in dispersed islet cells using shRNA (Figure 8, H–P). Similar to the inhibitor experiment, knockdown of either ATF6 or IRE1 expression reduced glucose-induced BrdU incorporation.

**ATF6 is necessary and sufficient to drive β cell proliferation.**

Three canonical pathways constitute the UPR response: PERK/eIF2α, IRE1/XBP1, and ATF6 (3, 7). All 3 of these pathways were activated by glucose in primary mouse islet cell cultures (Figure 2, F–J). To determine whether one or more of these pathways mediate the proliferative response to glucose in the β cell, each pathway was inhibited individually in primary mouse islet cell cultures using small molecules (Supplemental Figures 3 and 11; refs. 37–39). Glucose-induced proliferation was reduced by both the ATF6 and IRE1 inhibitors, but was not affected by the PERK inhibitor (Figure 8A). In contrast, none of these inhibitors reduced cell-cycle entry caused by cyclin D2 overexpression, arguing against non-specific toxicity (Figure 8A). Immunoblots showed that the ATF6 and IRE1 inhibitors, but not the PERK inhibitor, also reduced PCNA abundance in primary islet cell cultures (Figure 8B). To test whether activating the IRE1 or ATF6 pathways induced β cell proliferation, electroporation was used to overexpress IRE1, spliced (active) XBP1, or ATF6 in primary mouse islet cells (Figure 8, C–G, and Supplemental Figure 12). Surprisingly, given that the IRE1 inhibitor reduced proliferation, overexpression of either IRE1 or sXBP1 also reduced β cell proliferation in 15 mM glucose (Figure 8, D and G). ATF6 overexpression, however, was sufficient to increase β cell proliferation (Figure 8G). To test whether IRE1 or ATF6 were required for glucose-induced proliferation, expression was reduced in dispersed islet cells using shRNA (Figure 8, H–P). Similar to the inhibitor experiment, knockdown of either ATF6 or IRE1 expression reduced glucose-induced BrdU incorporation.
The Journal of Clinical Investigation

RESEARCH ARTICLE

Figure 7. UPR activation is required for insulin demand–induced β cell proliferation in vivo. (A) Twice daily i.p. injections of TUDCA for 2 days prior to euthanasia reduced β cell ER stress marker BiP in Akita and db/db-BLKS ER load models. Images are representative of n = 3 biological replicates. (B–G) Two days of twice daily i.p. TUDCA reduced β cell proliferation in 2-week-old Akita mice (B and C; n = 3–5), in 4-week-old db/db mice (D and E; n = 5–13), and in HFD-fed mice (F and G; n = 5–8). Images were acquired at ×200 magnification. Arrowheads point to BrdU-positive β cells. Data are represented as mean ± SEM; *P < 0.05 and **P < 0.01 by ANOVA.

(Figure 8, I and J). However, only ATF6 knockdown significantly decreased PCNA abundance (Figure 8, K–P). In sum, these results suggest that ATF6 is necessary and sufficient for glucose-induced proliferation in mouse β cells and that IRE1/XBP perturbation in either direction interferes with proliferation, but the pathway is not sufficient to drive proliferation.

**UPR modulates proliferation in human β cells.** Given the important differences between mouse and human β cells (40, 41), findings in mice must be tested in human samples to confirm potential medical relevance. We tested islet cells from 12 human donors (Supplemental Tables 2 and 3) to see whether UPR regulates β cell proliferation. Dispersed islet cells were cultured on glass coverslips in the presence of 7.5 or 15 mM glucose, plus activators or inhibitors of UPR (Figure 9, A–G). Proliferation increased in β cells from all donors when exposed to 15 mM glucose, although the basal proliferation and degree of increase varied considerably among donors (Supplemental Figure 13). To determine whether UPR activation could increase proliferation in these samples, Tg and Tm were applied. Tg and Tm increased BiP abundance in human islet cells (Supplemental Figure 14). β cells from most donors increased proliferation when treated with low-dose UPR-inducing agents (Figure 9, C and D). Due to the prominent variability in human islet preparations, the results are expressed as normalized to the rate of proliferation.
in 7.5 mM glucose (raw data in Supplemental Figure 13). Islets from a single T2D donor were included; these β cells showed no proliferative response to UPR activation. γ-H2AX was detected infrequently in human islet cultures and did not colocalize with BrdU immunofluorescence in low-dose Tg- and Tm-treated cultures, suggesting the observed BrdU incorporation was not due to DNA damage (Supplemental Figure 15). β cells from 5 of 6 donors tested showed a reduction in glucose-induced proliferation when treated with TUDCA or PBA (Figure 9E and Supplemental Figures 13 and 14), suggesting the UPR may be required for glucose-induced proliferation in human β cells. To determine whether ATF6 mediates the proliferative response to glucose, human islet cell cultures were treated with either ATF6 inhibitor or overexpression of human ATF6 by adenovirus. Inhibiting ATF6 reduced proliferation in 15 mM glucose (Figure 9F) and overexpression of ATF6 increased proliferation in 15 mM glu-
Our observations link UPR activation in the β cell with the well-documented demand-driven proliferative expansion of β cell mass. The work presented here has several strengths. The hypothesis arose from an unbiased protein-based screen. The connection between UPR and demand-led β cell proliferation was tested both in human β cell mass. The work presented here has several strengths. The hypoth-

Figure 9. UPR is necessary and sufficient to increase human β cell proliferation, via ATF6. (A) Human islets were dispersed and cultured on glass coverslips for 96 hours, with BrdU added to culture medium for the entire duration. Arrowheads indicate BrdU-positive β cells. Fibroblast nuclei, which are larger than endocrine nuclei, are labeled F. (B) Human β cell proliferation increased in high glucose (n = 12). Because baseline proliferation varied widely among donors, subsequent panels show data normalized to the 7.5 mM proliferation rate. The raw, non-normalized data for each prep are in Supplemental Figure 13. (C and D) Low-dose Tg (20 mM, C) or Tm (10–100 ng/ml, D) increased human β cell proliferation (n = 6–12). (E) TUDCA and PBA reduced human β cell proliferation in 15 mM glucose (n = 6). (F and G) In 15 mM glucose, human β cell proliferation decreased in the presence of the ATF6 inhibitor (n = 7; F) and increased with overexpression of ATF6 (n = 4; G). (A) Images acquired at ×200 magnification. Data are represented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001, and †P < 0.0001 by ANOVA (C–E) or Student’s t test (B, F, and G).

cose (Figure 9G), suggesting that ATF6 promotes human β cell proliferation. In sum, these results suggest that human β cell proliferation may be regulatable by modulating UPR in general and ATF6 activity in particular. Figure 10 illustrates the concept of a therapeutic window of β cell stress that could be harnessed to expand β cell mass to prevent or treat diabetes.

Discussion

Our observations link UPR activation in the β cell with the well-documented demand-driven proliferative expansion of β cell mass. The work presented here has several strengths. The hypothesis arose from an unbiased protein-based screen. The connection between UPR and demand-led β cell proliferation was tested both in human β cell mass. The work presented here has several strengths. The hypoth-

Figure 9. UPR is necessary and sufficient to increase human β cell proliferation, via ATF6. (A) Human islets were dispersed and cultured on glass coverslips for 96 hours, with BrdU added to culture medium for the entire duration. Arrowheads indicate BrdU-positive β cells. Fibroblast nuclei, which are larger than endocrine nuclei, are labeled F. (B) Human β cell proliferation increased in high glucose (n = 12). Because baseline proliferation varied widely among donors, subsequent panels show data normalized to the 7.5 mM proliferation rate. The raw, non-normalized data for each prep are in Supplemental Figure 13. (C and D) Low-dose Tg (20 mM, C) or Tm (10–100 ng/ml, D) increased human β cell proliferation (n = 6–12). (E) TUDCA and PBA reduced human β cell proliferation in 15 mM glucose (n = 6). (F and G) In 15 mM glucose, human β cell proliferation decreased in the presence of the ATF6 inhibitor (n = 7; F) and increased with overexpression of ATF6 (n = 4; G). (A) Images acquired at ×200 magnification. Data are represented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001, and †P < 0.0001 by ANOVA (C–E) or Student’s t test (B, F, and G).

cose (Figure 9G), suggesting that ATF6 promotes human β cell proliferation. In sum, these results suggest that human β cell proliferation may be regulatable by modulating UPR in general and ATF6 activity in particular. Figure 10 illustrates the concept of a therapeutic window of β cell stress that could be harnessed to expand β cell mass to prevent or treat diabetes.

Discussion

Our observations link UPR activation in the β cell with the well-documented demand-driven proliferative expansion of β cell mass. The work presented here has several strengths. The hypothesis arose from an unbiased protein-based screen. The connection between UPR and demand-led β cell proliferation was tested both in human β cell mass. The work presented here has several strengths. The hypoth-

Figure 9. UPR is necessary and sufficient to increase human β cell proliferation, via ATF6. (A) Human islets were dispersed and cultured on glass coverslips for 96 hours, with BrdU added to culture medium for the entire duration. Arrowheads indicate BrdU-positive β cells. Fibroblast nuclei, which are larger than endocrine nuclei, are labeled F. (B) Human β cell proliferation increased in high glucose (n = 12). Because baseline proliferation varied widely among donors, subsequent panels show data normalized to the 7.5 mM proliferation rate. The raw, non-normalized data for each prep are in Supplemental Figure 13. (C and D) Low-dose Tg (20 mM, C) or Tm (10–100 ng/ml, D) increased human β cell proliferation (n = 6–12). (E) TUDCA and PBA reduced human β cell proliferation in 15 mM glucose (n = 6). (F and G) In 15 mM glucose, human β cell proliferation decreased in the presence of the ATF6 inhibitor (n = 7; F) and increased with overexpression of ATF6 (n = 4; G). (A) Images acquired at ×200 magnification. Data are represented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001, and †P < 0.0001 by ANOVA (C–E) or Student’s t test (B, F, and G).

cose (Figure 9G), suggesting that ATF6 promotes human β cell proliferation. In sum, these results suggest that human β cell proliferation may be regulatable by modulating UPR in general and ATF6 activity in particular. Figure 10 illustrates the concept of a therapeutic window of β cell stress that could be harnessed to expand β cell mass to prevent or treat diabetes.

Discussion

Our observations link UPR activation in the β cell with the well-documented demand-driven proliferative expansion of β cell mass. The work presented here has several strengths. The hypothesis arose from an unbiased protein-based screen. The connection between UPR and demand-led β cell proliferation was tested both in human β cell mass. The work presented here has several strengths. The hypoth-

Figure 9. UPR is necessary and sufficient to increase human β cell proliferation, via ATF6. (A) Human islets were dispersed and cultured on glass coverslips for 96 hours, with BrdU added to culture medium for the entire duration. Arrowheads indicate BrdU-positive β cells. Fibroblast nuclei, which are larger than endocrine nuclei, are labeled F. (B) Human β cell proliferation increased in high glucose (n = 12). Because baseline proliferation varied widely among donors, subsequent panels show data normalized to the 7.5 mM proliferation rate. The raw, non-normalized data for each prep are in Supplemental Figure 13. (C and D) Low-dose Tg (20 mM, C) or Tm (10–100 ng/ml, D) increased human β cell proliferation (n = 6–12). (E) TUDCA and PBA reduced human β cell proliferation in 15 mM glucose (n = 6). (F and G) In 15 mM glucose, human β cell proliferation decreased in the presence of the ATF6 inhibitor (n = 7; F) and increased with overexpression of ATF6 (n = 4; G). (A) Images acquired at ×200 magnification. Data are represented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001, and †P < 0.0001 by ANOVA (C–E) or Student’s t test (B, F, and G).

cose (Figure 9G), suggesting that ATF6 promotes human β cell proliferation. In sum, these results suggest that human β cell proliferation may be regulatable by modulating UPR in general and ATF6 activity in particular. Figure 10 illustrates the concept of a therapeutic window of β cell stress that could be harnessed to expand β cell mass to prevent or treat diabetes.
Linking UPR sensors with β cell mass expansion in response to insulin demand is, in hindsight, an obvious solution to the puzzle of β cell mass regulation. The cell type most tuned to insulin demand is the β cell, through precise glucose sensing. Unmet insulin demand increases proinsulin production at the RNA and protein level, and proinsulin synthesis activates UPR pathways (3, 7, 43). Since β cell mass expansion occurs by proliferation of mature β cells, the simplest model explaining how β cell proliferation initiates in response to insulin demand would invoke a β cell–intrinsic sensor of insulin demand, such as the UPR. Connecting UPR with proliferation may explain why stem cells don’t participate in β cell homeostasis because undifferentiated cells would not sense insulin demand. In fact, this concept suggests a new demand-driven model of tissue homeostasis, in which differentiated cells sense an unmet need for their function and produce new cells to meet that need.

Observations from medicine hint that demand-driven determination of organ size might also apply to other tissues and might contribute to some disease processes. Several endocrine cell types proliferate when hormone synthesis increases, including islet α cells as well as thyroid, parathyroid, and pituitary cells (44–47). In vitro and in vivo, using multiple tools that impact ER biology by different mechanisms. Using small molecules and genetic experiments in vitro, the proliferative signal was traced to the ATF6 branch of the UPR. Findings were extended to human islets.

Taken together, these studies have important implications. First, we have identified a new role for the classic UPR mechanism: promoting proliferation in tissue homeostasis of a secretory cell type. Although cancer biologists have implicated UPR pathways in tumor cell adaptation and spread (42), this is the first report to our knowledge showing a role for UPR in determining tissue cell number in normal physiology. Cell biologists have established the UPR as a strategy by which cells adapt resources to meet peptide synthesis needs while minimizing unnecessary ER volume (3, 7). To perform this function, UPR senses secretory peptide synthesis overload and triggers new lipid and peptide production to expand ER capacity on a per-cell basis. Our data suggest that UPR load sensors may direct adaptation of peptide synthesis not only at the level of the individual cell, but also at a whole-organ level, by increasing the number of cells through proliferation. Thus, from a physiology perspective, UPR may contribute to determination of organ size.
some clinical situations — such as goiter, Nelson’s syndrome, and parathyroid hyperplasia — the proliferation may require surgical or other intervention, at some risk to the patient (45, 48). Other non-endocrine cells that produce secretory-pathway peptides may also employ this mechanism. Understanding the root cause of these proliferative conditions is the first step to finding treatments.

Previous observations have hinted that UPR activation in vivo might promote β cell proliferation, although no studies have directly addressed this hypothesis until now. Inducing UPR by transgenic overexpression of mutant proinsulin or the islet amyloid polypeptide (49, 50), or by deletion of ER stress cell–death mediators CHOP or DPS (30, 51), was noted to increase islet size or β cell proliferation. In adult mice, reducing PERK expression increased β cell proliferation (52, 53). This is consistent with our observation that the PERK pathway is not responsible for the pro-proliferative UPR signal and supports the possibility that ATF6, responding to loss of PERK, might drive proliferation. Deletion of Xbp1 in β cells resulted in insulin-deficient diabetes, impaired insulin processing, and dilated ER, suggesting compensated ER stress; β cell proliferation was reduced (54). IRE1 was found to promote prostate cancer cell-line proliferation via XBP1 (55). In our experiments, although IRE1 inhibition reduced β cell proliferation, both IRE1 and XBP1 overexpression also reduced proliferation, a conundrum that is consistent with the known careful balance of IRE1 and XBP actions (54) and that requires further study. Whole-body Atf6-null mice have reduced pancreatic insulin content and accelerated decompensation in the setting of insulin resistance, which could be consistent with loss of β cell mass (56); however, mice lacking Atf6 in β cells are reported to develop normally (57).

In vitro studies in β cells have not thus far reported a pro-proliferative effect of UPR activation. This may be because many investigators use transformed cell lines for in vitro studies, and transformation overrides usual homeostatic proliferation mechanisms. The doses of Tg and Tm usually used in culture cause decompensation and cell death, and the proliferative effect is dependent on glucose concentrations not typically used in routine culture. Culture of primary islet tissue, while more cumbersome and expensive, is more relevant to the in vivo environment, at least with respect to proliferation studies.

In an important clue to the mechanism of this effect, proliferation induced by low-dose ER stressors in vitro was strictly dependent on glucose concentration of the culture medium, with proliferation observed in higher glucose but with decompensation markers and cell death found in lower glucose. Possible explanations for this observation include glucose dependence of stress response parameters and energy requirements of cell division. The glucose concentrations indicated refer to conditions at the start of the experiment; glucose abundance at the end of the experiments was not measured and may have been lower due to utilization. In low glucose, some hallmarks of the integrated stress response (ISR) were induced, including CHOP and cell death, while ATF6 was not increased (Figure 4, A, B, L, and Supplemental Figure 4C). Our findings are consistent with prior observations that ISR is activated in rat islets or the murine min6 pancreatic β cell line at 2 mM and 5 mM glucose, whereas UPR is activated in high glucose (58, 59). Glucose concentration may impact the degree, duration, or identity of transcripts affected by ISR-mediated translation block in β cells (60). Intriguingly, in HEK293T cells, the ISR preferentially reduces translation of MTOR-regulated genes (61); β cell proliferation is strictly dependent on MTOR activation (62). It is possible that glucose uptake may be heterogeneous among β cells, and the degree of glucose uptake may be related to both UPR activation and proliferation.

The work presented here suggests a possible approach to therapeutic expansion of β cell mass. However, β cells are sensitive to ER stress, which when unresolved is a primary cause of β cell loss in both autoimmune and obesity-related diabetes (3, 4, 6, 63–65). Placing UPR as the sensor of insulin demand that determines β cell number offers one explanation for this heightened susceptibility. Potential therapies utilizing UPR to promote β cell proliferation would have to take into consideration the current level of β cell stress and operate within a narrow safety window to avoid overload and cell death. It remains to be determined how the glucose dependence of UPR-induced proliferation observed in vitro translates to the in vivo condition. This work also raises the possibility that agents that reduce β cell stress from the decompensated range to the adaptive range might have the potential to reset the stress rheostat to enable mild stress to expand β cell mass. Tools are needed to measure, and to modulate, β cell stress level in vivo.

Translating mouse β cell findings to human tissue has been challenging (40, 41). Human β cells have lower basal proliferation than mouse and respond less well to stimulation (40, 41). Furthermore, islets from people with diabetes show evidence of decompensated ER stress (31, 64). Our finding that human β cells from most, but not all, donors proliferated in response to UPR offers a potential handle to move toward identifying the genetic, epigenetic, and acquired factors that impact human β cell mass accrual in response to insulin demand. UPR pathway activation is influenced by genetics in mice (29). Combined with means of measuring and modulating in vivo β cell stress, this knowledge may allow patient-specific therapies to enhance β cell mass.

Remaining areas of uncertainty include the nature of the precise signal that activates UPR, whether the adaptive proliferative response can be sustained under chronic ER stress conditions, and whether this is due to ER peptide load from proinsulin synthesis, ER redox status, calcium handling, or other insult. A role for ATF6 in demand-driven β cell mass in vivo has not yet been demonstrated. ATF6 targets that drive proliferation remain to be discovered. However, the current work represents an important step forward in understanding how β cell number adapts to insulin demand, and it may illustrate a new paradigm linking organ size to physiological need.

Methods

Mice. Glucose infusions were performed as described (15); 10- to 12-week-old C57BL/6j male mice received continuous i.v. infusions of saline (in the femoral vein for those performed at University of Pittsburgh School of Medicine, and in the jugular vein for those performed at UMass Medical School) or 50% dextrose for 4 days. They then were euthanized for islet isolation or pancreas histology. High-fat feeding was performed as described (28); 10- to 12-week-old C57BL/6j male mice were fed control chow or 60% lard diet (catalog TD.06414, Harlan) for 7 days. INS2(C96YAkita) mice or db/db-C57BLKS mice (both from The Jackson Laboratory) were studied, with littermate controls.
Males and females showed similar results and were combined. For TUDCA experiments, mice were injected i.p. with 500 μg/kg TUDCA or saline (HFD-fed mice) or PBS (Akita and db/db mice) twice daily for 2 days prior to sacrifice. To measure proliferation, for HFD, mice received 40 mg/kg BrdU i.p. twice daily (am and pm) for 2 days with the TUDCA injections. Akita and db/db mice received 2 injections of 40 mg/kg BrdU at 4 hours and 2 hours prior to euthanasia. Two hours after the final injection, mice were euthanized and pancreata processed for histology. Blood glucose measurements were completed by AlphaTRAK glucometer (Abbott).

**Mouse islet isolation, dispersion, and culture.** Islets were isolated as described (24), by collagenase digestion and ficoll-hypaque density gradient separation. For all primary islet cell experiments, islets were cultured overnight in islet complete media (ICM, RPMI containing 10% FBS, penicillin/streptomycin, and 5 mM glucose). The following day, islets were hand-picked and trypsinized (0.05% trypsin), and single cells were plated on uncoated coverslips for immunofluorescence or on uncoated plastic for Western blots and RNA. To minimize variability, dispersed-islet proliferation assays, FBS from a single vendor (Atlantic Biologicals), and lot was used; islet culture medium was mixed in bulk and stockpiled in small volumes; and trypsin for islet dispersion was frozen in single-use tubes. Controls were performed on each biological replicate to minimize impact of variability on experimental result. When an experiment required more islets than were obtainable from one mouse, islets from multiple mice were pooled to achieve one biological replicate. Treatments were administered for 72 hours for immunoblots and immunostaining (final 24 hours with BrdU), or 6, 24, or 48 hours for quantitative PCR (qPCR).

**Proteomics screen.** C57BL/6J 10- to 12-week-old male mice were infused for 4 days with saline or glucose, as above. Pancreatic islets were isolated and hand-picked on ice in ICM containing 1% FBS. Islet lysates from 4 mice in each condition were pooled, labeled with Cy3 or Cy5 (University of Pittsburgh Proteomics Core), combined, focused to 70,000 volt-hours (IPGphor power source, Bio-Rad) on Immobiline pH 4-10 isoelectric focusing strips, and separated by SDS-PAGE (66). Gel images (Typhoon scanner, GE Healthcare) were visually evaluated for spot intensity change. Gels were poststained with Coomassie (Bio-Rad) and 24 proteins of interest were manually excised (OneTouch, The Gel Co.). Following trypsin digestion (Trypsin Gold, Promega), peptides were eluted, dehydrated, dissolved in 50% acetonitrile/0.3% trifluoroacetic acid/1 mM citric acid with an equal volume of saturated α-cyan-4-hydroxy cinnamic acid, and spotted on a MALDI plate (Applied Biosystems). MALDI-TOF analysis, performed on an ABI 4700 Mass Spectrometer at the University of Pittsburgh Integrated Proteomics screen, was visually evaluated for spot intensity change. Gels were poststained with Coomassie (Bio-Rad) and 24 proteins of interest were manually excised (OneTouch, The Gel Co.). Following trypsin digestion (Trypsin Gold, Promega), peptides were eluted, dehydrated, dissolved in 50% acetonitrile/0.3% trifluoroacetic acid/1 mM citric acid with an equal volume of saturated α-cyan-4-hydroxy cinnamic acid, and spotted on a MALDI plate (Applied Biosystems). MALDI-TOF analysis, performed on an ABI 4700 Mass Spectrometer at the University of Pittsburgh Integrated Proteomics Core Facility, identified 18 unique proteins (Supplemental Table 1).

**Immunoblots.** Islet cells were washed with PBS and lysed in 125 mM/1 Trit, 2% SDS, 1 mm/mL dithiothreitol, 20 μg/mL 4-aminophenylmethylsulfonyl fluoride hydrochloride (APMSF), and protease inhibitors, directly added to the culture well. Cells were detached from the plastic with a cut pipette tip, and samples were sonicated for 10 minutes on ice. After separation on SDS-PAGE, proteins were transferred to PVDF membrane, and the membrane was then blocked for 1–2 hours with 5% skim milk powder containing PBS and 0.1% Tween-20. Membranes were probed with antibodies from Abcam (p-IRE1, catalog ab124945), BD Biosciences (BiP, catalog 610978), Cell Signaling Technology (sXBP, catalog 12782; CHOP, catalog 2895; activated caspase 3, catalog 9661; GRP94, catalog 2104; p-eIF2α, catalog 9721; PDI, catalog 2446; and IRE1, catalog 5294), EMD Millipore (actin, catalog MAB1501; Cre, catalog 690500), Imagezen (ATF6, catalog IMG-273, Novus Biologicals (ATF6, catalog NB1-40256), Santa Cruz Biotechnology Inc. (PCNA, catalog sc-56), and Sigma-Aldrich (Flag, catalog F1804). Blots were developed using ECL, ECL prime (GE Healthcare) or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific). Band intensity was quantified using ImageJ (NIH).

**RNA isolation and qPCR.** RNA was isolated from intact islets (in vivo glucose infusion) or dispersed islets (cell culture experiments) using an all-in-one RNA purification kit (Norgen Biotek Corp.). RNA quality and quantity were verified by RNA integrity number and Nanodrop. cDNA was synthesized from 100–500 ng total RNA using iScript cDNA synthesis kit (Bio-Rad). qPCR was performed using SYBR green detection on RealPlex 2 and 4 cyclers (Eppendorf). For the semi-quantitative gel-based assay for Xbp splicing, cDNA amplified at 98°C for 2 minutes, 29 cycles of 98°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds, and final extension at 72°C for 5 minutes was run on a 2% agarose gel and imaged using a GelDoc (UVP LLC.). Primers were obtained from the literature (Supplemental Table 4). Data are expressed as ddCt (fold change). For XBP1 splicing, semi-qPCR was followed by agarose electrophoresis; bands were quantified using ImageJ (NIH).

**Flow cytometry.** After culture treatments, dispersed islet cells were detached from the plate using trypsin. Cells in suspension were either not fixed (for Annexin V/PI staining) or fixed with 4% PFA for 20 minutes on ice. Cells were then washed twice with ice-cold PBS and left at 4 degrees until staining. On the day of staining, cells in PBS were centrifuged and fixed again for 5 minutes on ice with BD cytofix/cytoperm buffer (BD Biosciences). After washing, cells were resuspended in DPBS containing 300 μg/ml DNase for DNA digestion for BrdU staining. Cells were incubated at 37°C for 1 hour and then washed with BD perm/wash buffer (BD Biosciences). Staining was performed using anti-insulin-488 antibody (Cell Signaling Technology), BrdU-PE (BioLegend), and unconjugated mouse–BiP antibody for 20–30 minutes on ice. After washing, anti-mouse APC-labeled antibody was added for 20–30 minutes. For culture cell counts, samples were prepared as above, without DNase, and with an additional label using mouse anti-glucagon conjugated to Zenon Pacific Blue (Invitrogen). Cells were counted at the same speed for a fixed time for each sample to assess relative cell number. Experiments were analyzed using an LSRII flow cytometer (BD Biosciences) and FlowJo software. Annexin V/PI staining was performed according to the manufacturer’s protocol (Millipore), with analysis using a BD Accuri C6 flow cytometer (BD Biosciences) and FlowJo software.

**IHC and immunocytochemistry.** Pancreas and gut were fixed with 4% formalin (v/v) at room temperature for 5 hours and embedded in paraffin. Five to 7 micron sections were blocked and labeled using primary antibodies listed below and with DyLight secondary antibodies (Jackson ImmunoResearch Laboratories Inc.). For immunocytochemistry, dispersed islet cells were fixed with 4% paraformaldehyde for 10 minutes at room temperature. For BrdU staining, slides or coverslips were preincubated in 1N HCl for 30 minutes at 37°C prior to block step. Antibodies used for immunostaining were from Abcam (BrdU, catalog ab6326; insulin, catalog ab7842), BD Biosciences (BiP, catalog 610978), Cell Signaling Technology (γ-H2AX, cat-
aolog 9718; pH7.3, catalog 3377), and Santa Cruz Biotechnology Inc. (PCNA, catalog sc-56). Images were acquired using a Nikon fluorescence microscope, blinded, and manually counted. For transcription electron microscopy, pancreas was fixed in 2.5% glutaraldehyde/2% paraformaldehyde and postfixed in aqueous 1% OsO₄, 1% K₄Fe(CN)₆. After dehydation through a graded ethanol series, samples were infiltrated in a 1:1 mixture of propylene oxide/Polybed 812 epoxy resin (Polysciences Inc.), embedded, cured at 37°C overnight, and hardened at 65°C for 2 more days. Ultrathin (70 nm) sections were collected on 200 mesh copper grids and stained with 2% uranyl acetate in 50% methanol for 10 minutes, followed by 1% lead citrate for 7 minutes. Sections were imaged using a JEOL JEM 1011 transmission electron microscope at 80 kV fitted with a side mount AMT digital camera (Advanced Microscopy Techniques).

Transfection and adenoviral infection. Plasmids were obtained from Addgene (ATF6a, IRE1α, and shXbp) or OriGene (sh-ATF6 and sh-IRE1). Islets were dispersed to single cells and washed with PBS. Plasmid was added, cells were electroporated at 950 mV with 2 shocks of 20 ms using the Neon transfection system (Invitrogen). Viability before and after electroporation (Supplemental Figure 12) was measured by adding 1 µl of TO-PRO-3 (Invitrogen) to cells suspended in 100 µl of PBS, followed by flow cytometry on a BD LSRII and analysis using FlowJo software. Dispersed transfected cells were plated on plastic for Western blot or on coverslips for immunocytochemistry, where they were allowed 24 hours to recover prior to treatment. Adenovirus expressing mouse Cyclin D2 or control (Vector BioLabs) was used at 10 MOI to transduce dispersed islet cells on the day after plating.

Human islet culture. Human islets received from Integrated Islet Distribution Program (IIDP) were allowed to recover in ICM for 24–48 hours. Islets were picked, dispersed, and plated on coverslips as above, except that treatments with glucose and drugs were for 96 hours, with BrdU added at the start of the treatment. The percent of β cells of human islet preparations was determined by dividing the total number of nuclei, as determined by DAPI staining, by the number of insulin-stained cells, in the control 7.5 mM glucose condition using images obtained for the experiment shown in Figure 9A. Adenovirus expressing human ATF6 or control (Vector BioLabs) was used at 10 MOI to transduce dispersed human islet cells the day after plating. After 96 hours, cells were fixed and stained as above.

Chemicals. Chemicals used included Tg (doses per test), TUDCA (100 ng/ml), PBA (250 nM), and Brdu (40 mg/kg) (all from Sigma-Aldrich), along with Tm (doses per test), ATF6 inhibitor AEBSF (100 nM), PERK inhibitor GSK2606414 (5 nM), and IRE1 inhibitor 4µ8c (7 µM) (all from EMD).

Statistics. Data are represented as mean ± SEM of n independent mice or independent islet preparations. Statistical analyses were performed using Prism (GraphPad). P values are calculated by 2-tailed Student’s t test or 1-way ANOVA with Sidak post-test for multiple comparisons; P < 0.05 was considered significant.

Study approval. Mice were maintained at UMass Medical School or the University of Pittsburgh. All procedures were approved by their respective Institutional Care and Use Committees.

Acknowledgments
Human pancreatic islets were provided by the NIDDK-funded IIDP at City of Hope. We thank the University of Pittsburgh Proteomics Core, Integrated Core Facility, and Donna Stolz at the Center for Biological Imaging for assistance with the proteomics screen and electron microscopy, respectively, and the National Mouse Metabolic Phenotyping Center at UMass Medical School, supported by U24-DK093000, to Jason Kim. This study was funded by the NIH: DK076562 (to L.C. Alonso), DK095140 (to L.C. Alonso), and DK48280 (to P. Arvan). We are also grateful for many important discussions with our friends and colleagues and the Beta Cell Group at UMass.

Address correspondence to: Laura C. Alonso, Diabetes Division, UMass Medical School, 368 Plantation Street, Worcester, Massachusetts 01605, USA. Phone: 774.455.3640; E-mail: Laura. Alonso@umassmed.edu.


